Rabo Equity’s India nutrition play
Valued at around INR720 billion ($11.9 billion), India’s pharmaceutical market continues to be a popular destination with private equity investors, but the sector has seen better days. A recent report by PricewaterhouseCoopers shows a tightening regulatory environment – in particular new rules on drug pricing – led to sector growth slowing to 9.8% in 2013 against 16.6% the year before.
Contrast this with nutraceuticals - the burgeoning market for nutritional food and beverage supplements - which has not suffered from the same constraints. The sector continues to see compound annual growth...
Latest News
Asian GPs slow implementation of ESG policies - survey
Asia-based private equity firms are assigning more dedicated resources to environment, social, and governance (ESG) programmes, but policy changes have slowed in the past 12 months, in part due to concerns raised internally and by LPs, according to a...
Singapore fintech start-up LXA gets $10m seed round
New Enterprise Associates (NEA) has led a USD 10m seed round for Singapore’s LXA, a financial technology start-up launched by a former Asia senior executive at The Blackstone Group.
India's InCred announces $60m round, claims unicorn status
Indian non-bank lender InCred Financial Services said it has received INR 5bn (USD 60m) at a valuation of at least USD 1bn from unnamed investors including “a global private equity fund.”
Insight leads $50m round for Australia's Roller
Insight Partners has led a USD 50m round for Australia’s Roller, a venue management software provider specializing in family fun parks.